News
INO
5.52
+1.28%
0.07
Weekly Report: what happened at INO last week (1028-1101)?
Weekly Report · 1d ago
Earnings week ahead: O, PLTR, QCOM, SQ, AMC, PARA, LCID, RIVN, WBD, and more
Seeking Alpha · 1d ago
Warning: INO is at high risk of performing badly
Seeking Alpha · 1d ago
Weekly Report: what happened at INO last week (1021-1025)?
Weekly Report · 10/28 09:26
Reported Earlier, 'New Mpox Variant Detected In Germany: Health Authority' - The Economic Times
Benzinga · 10/22 15:08
Inovio’s INO-3107 shows efficacy in recurrent respiratory papillomatosis
TipRanks · 10/21 12:10
INOVIO Presents Data on INO-3107's Immune Response Against HPV-6 and HPV-11
Benzinga · 10/21 12:03
INOVIO PHARMACEUTICALS INC - 81% OF PATIENTS EXPERIENCED FEWER SURGICAL INTERVENTIONS POST-TREATMENT WITH INO-3107
Reuters · 10/21 12:00
INOVIO PHARMACEUTICALS INC - INO-3107 WELL TOLERATED, MOST FREQUENT AES WERE INJECTION SITE PAIN AND FATIGUE
Reuters · 10/21 12:00
Weekly Report: what happened at INO last week (1014-1018)?
Weekly Report · 10/21 09:26
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
NASDAQ · 10/16 15:01
Weekly Report: what happened at INO last week (1007-1011)?
Weekly Report · 10/14 09:32
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
NASDAQ · 10/09 09:38
Weekly Report: what happened at INO last week (0930-1004)?
Weekly Report · 10/07 09:29
The Analyst Verdict: Inovio Pharmaceuticals In The Eyes Of 4 Experts
Benzinga · 10/04 20:02
Inovio Pharma Price Target Cut to $7.00/Share From $8.00 by RBC Capital
Dow Jones · 10/04 15:53
Inovio Pharma Is Maintained at Sector Perform by RBC Capital
Dow Jones · 10/04 15:53
Inovio Pharmaceuticals: Takes Another Torpedo But Keeps On Sailing
Seeking Alpha · 09/30 15:29
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.